Sign Up Today and Learn More About Kailera Therapeutics Stock
Invest in or calculate the value of your shares in Kailera Therapeutics or other pre-IPO companies through EquityZen's platform.
Kailera Therapeutics Stock
Kailera Therapeutics is a clinical-stage biotechnology company that provides therapies for treating obesity and related diseases.
About Kailera Therapeutics Stock
Founded
2024
Headquarters
Waltham, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Kailera Therapeutics Press Mentions
Stay in the know about the latest news on Kailera Therapeutics
Amid a tough year for biotech, these Mass. companies just raised $1B
masslive • Oct 22, 2025
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
biospace • Oct 21, 2025
Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025
globenewswire • Oct 21, 2025
DayOne eyes $1 billion+ funding at up to $5 billion valuation to expand data centers across Asia and Europe
techstartups • Oct 18, 2025
The Week’s 10 Biggest Funding Rounds: Biotech Dominates A Busy Week
news • Oct 17, 2025
Kailera Therapeutics Management
Leadership team at Kailera Therapeutics
Founder, President & CEO
Ron Renaud
CTO
Doug Bakan
Join now and verify your accreditation status to gain access to:
- Kailera Therapeutics Current Valuation
- Kailera Therapeutics Stock Price
- Kailera Therapeutics Management
- Available deals in Kailera Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Kailera Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Kailera Therapeutics Revenue and Financials
- Kailera Therapeutics Highlights
- Kailera Therapeutics Business Model
- Kailera Therapeutics Risk Factors
- Kailera Therapeutics Research Report from SACRA Research
Trading Kailera Therapeutics Stock
How to invest in Kailera Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Kailera Therapeutics through EquityZen funds. These investments are made available by existing Kailera Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Kailera Therapeutics stock?
Shareholders can sell their Kailera Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 400K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 49K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."